Printer Friendly

OUTCOME OF INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION/ISHOD NAKON AKUTNOG ISHEMIJSKOG MOZDANOG UDARA LECENOG INTRAVENSKOM TROMBOLIZOM KOD PACIJENATA SA ATRIJALNOM FIBRILACIJOM I BEZ NJE.

Summary

Introduction. Atrial fibrillation is associated with an increased risk of ischemic stroke. The benefit of intravenous thrombolysis in patients with acute ischemic stroke and atrial fibrillation is still unclear. The aim of the study was to assess and compare the effects of intravenous thrombolysis in stroke patients with and without atrial fibrillation. Material and Methods. We analyzed stroke patients who were treated with intravenous thrombolysis. Patients were divided into two groups according to the presence of atrial fibrillation. Demographic, clinical and radiological characteristics of patients were compared between the two groups. The treatment efficacy was evaluated in relation to the improvement of neurological status after 24 hours, and functional recovery after three months. Binary logistic regression was used to evaluate predictors of outcome. Results. From a total of 188 patients, 39.4% presented with atrial fibrillation. Patients with atrial fibrillation were older (69.4 vs. 62.6 years; p <0.0001), with female predominance (43.2% vs. 28.9%, p = 0.04) and had clinically more severe stroke (National Institutes of Health Stroke Scale, score on admission 15.4 vs. 12.1; p = 0.0001). Significantly more patients without atrial fibrillation (61.4% vs. 43.2%, p = 0.01) had a favorable clinical outcome at three months after stroke. Nevertheless, atrial fibrillation was not an independent predictor of poor outcome at three months after stroke (p=0.66). Conclusion. Acute ischemic stroke patients, with atrial fibrillation, treated with intravenous thrombolysis, had worse outcomes than patients without atrial fibrillation did. However, it is mainly due to older age and a more severe stroke in patients with atrial fibrillation.

Key words: Stroke; Brain Ischemia; Thrombolytic Therapy; Atrial Fibrillation; Treatment Outcome; Neurologic Manifestations; Fibrinolytic Agents; Tissue Plasminogen Activator; Severity of Illness Index; Risk Factors

Sazetak

Uvod. Atrijalna fibrilacija nosi povisen rizik za nastanak ishemijskog mozdanog udara. Benefit intravenske trombolize kod pacijenata sa mozdanim udarom nastalim zbog atrijalne fibrilacije je jos uvek nedovoljno jasan. Cilj rada bio je procena efikasnosti intravenske trombolize kod pacijenata sa mozdanim udarom i atrijalnom fibrilacijom u poredenju sa onima bez atrijalne fibrilacije. Materijal i metode. Analizirani su pacijenati koji su leceni intravenskom trombolizom zbog akutnog ishemijskog mozdanog udara. Pacijenti su podeljeni u dve grupe u odnosu na prisustvo atrijalne fibrilacije. Demografske, klinicke i radioloske karakterstike pacijenata poredene su izmedu dve grupe. Efikasnost je procenjivana u odnosu na poboljsanje neuroloskog nalaza nakon 24 sata i funkcionalni oporavak nakon tri meseca od mozdanog udara. Binarnom logistickom regresijom odredivani su prediktori ishoda. Rezultati. Od ukupno 188 pacijenata, njih 39,4% imalo je atrijalnu fibrilaciju. Ovi pacijenti su bili stariji (69,4 naspram 62,6 godina, p < 0,0001), cesce zenskog pola (43,2% naspram 28,9%, p = 0,04) i imali su klinicki tezi mozdani udar (Nacionalni vodic za skor kod akutnog ishemijskog mozdanog udara na prijemu 15,4 naspram 12,1, p = 0,0001) u odnosu na pacijente bez atrijalne fibrilacije. Dobar klinicki ishod nakon tri meseca imalo je znacajno vise pacijenata bez atrijalne fibrilacije (61,4% naspram 43,2%, p = 0,01). Ipak atrijalna fibrilacija nije bila nezavisan prediktor loseg ishoda (p =0.66). Zakljucak. Pacijenti sa ishemijskim mozdanim udarom i atrijalnom fibrilacijom leceni intravenskom trombolizom imaju losiji ishod u odnosu na one bez atrijalne fibrilacije, ali je to prevashodno posledica starijeg zivotnog doba i tezeg mozdanog udara ovih pacijenata. Kljucne reci: mozdani udar; mozdana ishemija; tromboliticka terapija; atrijalna fibrilacija; ishod lecenja; neuroloske manifestacije; fibrinoliticki agensi; aktivator tkivnog plazminogena; indeks tezine bolesti; faktori rizika

Introduction

Atrial fibrillation (AF) is the most common heart rhythm disorder, occurring in 2% of the general population, and in 20% of persons older than 80 years [1]. Its incidence increases with age, and doubles in each decade of life after the age of 55 years. Due to the extremely high embolic potential, AF is the most important cardiac risk for the development of cardio-embolic stroke [2-4]. The cardio-embolic stroke clinically manifests as a severe neurological deficit, and radiologically as a territorial (non-lacunar) infarction.
Abbreviations

AF         --  atrial fibrillation
IVT        --  intravenous thrombolysis
rtPA       --  recombinant tissue plasminogen activator
AIS        --  acute ischemic stroke
NIHSS      --  national institutes of health stroke scale
ICH        --  intracranial hemorrhage
CT         --  computed tomography
ASPECT     --  Alberta stroke program early computed tomography
OTT        --  onset-to-treatment time
HT         --  hemorrhagic transformation
sICH       --  symptomatic intracranial hemorrhage
ECASS III  --  European cooperative acute stroke study III
OCSP       --  Oxfordshire community stroke project
TACI       --  total anterior circulation infarction
PACI       --  partial anterior circulation infarction
POCI       --  posterior circulation infarction
LACI       --  lacunar infarction
MR         --  magnetic resonance
mRS        --  modified Rankin score
ECG        --  electrocardiography
OR         --  odds ratio
CI         --  confidence interval


Until recently, intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rtPA) was the only approved therapy for the treatment of patients with acute ischemic stroke (AIS) [5, 6], improving the outcome if applied within 4.5 hours after the onset of symptoms [7]. However, whether IVT is effective in AIS patients with AF is still insufficiently clear. Large studies have proven the benefits of IVT, but without testing the treatment efficacy in regard to the type and etiology of stroke [7]. Some authors have shown that AF is a predictor of a poor outcome in AIS patients treated with IVT [8], although there are also opposite results [9]. Even today, the attitudes on the efficacy and safety of IVT in AIS patients with AF are still quite controversial.

The aim of our study was to evaluate the efficacy and safety of IVT in AIS patients with AF compared to AIS patients without AF.

Material and Methods

This cross-sectional study analyzed the data of patients with AIS who were treated with IVT at the Clinical Center of Vojvodina in Novi Sad, Serbia. The data were prospectively collected in the period from November 2008 to April 2015. On admission, all patients were examined by a neurologist and their National Institute of Health Stroke Scale (NIHSS) score was determined. This score is used for assessment of severity of stroke and correlates with the size of cerebral infarction [10]. All patients underwent brain computed tomography (CT) in or-der to exclude intracranial hemorrhage (ICH). The Alberta Stroke Program Early CT (ASPECT) score, that reflects the size of the cerebral ischemia [11], presence of a hyperdense artery sign and leukoaraiosis, were assessed by a radiologist. The following data were also recorded: age, gender, risk factors (arterial hypertension, diabetes mellitus, hyperlipidemia, and smoking), glucose level on admission, previous use of antiplatelet and statin therapy, and the symptom onset-to-treatment time (OTT).

Twenty-four hours following the IVT treatment, the NIHSS score was determined again and brain CT was repeated. Neurological improvement showed a reduction in the NIHSS score of [greater than or equal to] 50% compared with the NIHSS score on admission, or as NIHSS score [less than or equal to] 3. Based on repeated CT findings, we determined the type of cerebral infarction, and possible presence of hemorrhagic transformation (HT). Development of symptomatic intracranial hemorrhage (sICH) in the early stages of AIS (within seven days) was assessed according to the European Cooperative Acute Stroke Study III (ECASS III) criteria [12]. The type of brain infarction was determined in accordance with the Oxfordshire Community Stroke Project (OCSP) classification [13]. According to OCSP classification, there are four types of cerebral infarction: total anterior circulation infarction (TACI), partial anterior circulation infarction (PACI), posterior circulation infarction (POCI) and lacunar infarction (LACI). All patients underwent neurovascular status evaluation with ultrasound (carotid duplex ultrasound, transcranial Doppler) and/or CT or magnetic resonance (MR) angiography examinations. Functional outcome was assessed after three months by the modified Rankin score (mRS) and favorable outcome was defined as mRS 0-2 and unfavorable as mRS 3-6.

The presence of AF was defined as an evidence of these arrhythmias on at least one electrocardiographic (ECG) recording, obtained either from medical history or during hospitalization. After admission, patients were monitored with ECG for at least 72 hours and, if necessary, had additional recordings.

Patients were divided into two groups, according to the presence or absence of AF, and they were compared with regard to demographic, clinical and radiological characteristics, outcomes and adverse events. The two-sample student t-test was used for comparisons of parametric variables and chi-square ([chi] (2)) test or Fisher's exact test for categorical variables. A p value of less than 0.05 (p < 0.05) was regarded statistically significant. Binary logistic regression analysis was used to evaluate predictors of neurological improvement, favorable outcome and HT. The variables which were analyzed included age, gender, baseline NIHSS score, OTT, glucose level on admission, presence of AF and other risk factors (arterial hypertension, diabetes mellitus, hyperlipidemia, smoking). Odds ratio (OR) was calculated with 95% confidence interval (95% CI). Data were analyzed with the SPSS/PC Win package version 20.0. The study was approved by the Ethical Board of the Clinical Center of Vojvodina.

Results

The study included a total of 188 patients. Among them, 74 patients (39.4%) had AF and 114 patients (60.6%) were without AF. Demographic, clinical and radiological characteristics, as well as stroke subtypes of the two groups are shown in Table 1. Patients with AF were older (69.4 vs. 62.6, p<0.0001) and there were more female patients (43.2% vs. 28.9%, p=0.04). In regard to risk factors, only smoking was significantly more frequent among patients without AF (35.09% vs. 17.57%; p=0,009). Time from symptom onset to thrombolytic treatment (OTT) did not differ significantly between the two groups of patients. Regarding other clinically significant characteristics, only previous use of antiplatelet therapy was significantly more frequent in patients with AF (48.65% vs. 28.07%, p=0.004). On average, patients with AF had a more severe stroke, i.e., a higher NIHSS score on admission (15.0 vs. 12.1, p<0.0001). The average baseline ASPECT score on brain CT did not differ significantly between the two groups of patients. In patients with AF, the most frequent were total and partial anterior circulation infarctions (TACI 47.3%; PACI 45.9%), whereas lacunar infarctions were significantly more frequent in patients without AF (LACI type 21.9% vs. 2.7%).

The outcome at 90 days post treatment is shown in Graph 1. Approximately half of the patients without AF had a mRS score of 0 or 1 (mRS 0-23.1 %, mRS 1-25.4%), whereas majority of patients with AF had mRS 6 (29.7%).

Comparison of outcomes and complications after application of IVT is shown in Table 2. Neurological improvement at 24 hours was more frequent in patients without AF (42.1% vs. 31.1%), although without a statistical significance. A good outcome at three months (mRS 0 - 2) was significantly more frequent in patients without AF (61.4% vs. 43.2%; p=0.01). Furthermore, patients with AF commonly had a significant hemorrhagic transformation (29.7% vs. 10.5%; p=0.0008), as well as symptomatic intra-cerebral hemorrhage (9.5% vs. 0%; p=0.001). Lethal outcome (mRS 6) within 90 days post treatment was also more frequent in patients with AF (31.08% vs. 7.89%; p<0.0001).

The binary logistic regression analysis did not show AF to be an independent predictor of poor (p=0.66) or lethal outcome (p=0.17) at three months post IVT for AIS. In our study, predictors of an unfavorable outcome (mRS 3 - 6) at three months were: older age (p<0.0001; OR 1.08, 95% CI 1.03-1.13), a higher NIHSS score on admission (p<0.0001; OR 1.31, 95% CI 1.19-1.45), a lower AS PECT score on admission (p=0.013; OR 0.64, 95% CI 0.45-0.91) and higher glucose levels on admission (p<0.0001; OR 1.28, 95% CI 1.13-1.45). Predictors of lethal outcome (mRS 6) at three months were older age (p<0.0001; OR 1.15, 95% CI 1.08-1.23), a higher NIHSS score on admission (p<0.0001; OR 1.35, 95% CI 1.18-1.54) and presence of diabetes (p=0.003; OR 5.95, 95% CI 1.86-18.97). In addition, AF was not independently associated with neurological improvements at 24 hours (p=0.38). Predictors of neurological improvement at 24 hours were a lower NIHSS score on admission (p=0.003; OR 0.89, 95% CI 0.83-0.96), a higher ASPECT score (p=0.027; OR 1.44, 95% CI 1.04-1.99) and absence of diabetes (p=0.008; OR 0.27, 95% CI 0.1-0.7). However, AF was independently associated with development of hemorrhagic transformation (p<0.0001; OR 4.44, 95% CI 1.92 - 10.27).

Discussion

Our study showed that AIS patients with AF treated with IVT had a worse outcome than patients without AF. Patients with AF were older (7 years, on average) and clinically had a more severe stroke (NIHSS score higher by around 3 points) compared to patients without AF. Higher NIHSS score in patients with AF was a result of larger cerebral infarction in patients with AF. Lacunar infarction was found only in 2.7% of patients (two patients) with AF, versus 21.9% of patients without AF. Development of HT and sICH was significantly more frequent in patients with AF. Similar results have been reported in some other studies [8, 14, 15]. In a Japanese study of 85 patients, including 51.8% of patients with AF, neurological improvement at seven days post IVT was considerably lower in patients with AF (31.8% vs. 60%; p = 0.007) [8]. In addition, a favorable outcome (mRS 0 - 2) at three months was also recorded in significantly fewer patients with AF compared to those without AF (15.9% vs. 46.3%, p = 0.002). Another study included 734 patients, of whom 21.1% had AF, a poor outcome (mRS 3-6) was reported in 52.3% of patients with AF and in 35.2% of patients without AF (p < 0.001) [14]. The mortality at 3 months following stroke was 21.9% in the group with AF and 9% in the group without AF. Correspondingly, we found a higher percentage of poor outcome and a higher mortality rate in the group of patients with AF within three months following IVT. In a recent study which examined predictors of early neurological improvement, AF was independently associated with the absence of the major neurological improvement 24 h after IVT [15]. In our study, early neurological im provement was more common in patients without AF, but it was not significant.

In the above-mentioned studies [8, 14], patients with AF were also older and had a higher NIHSS score and more frequent HT, compared to patients without AF, which is consistent with our findings. All of these characteristics (older age, higher NIHSS score, common HT) are typical of ischemic stroke caused by AF. As numerous studies have shown that age and the NIHSS score on admission are the most important predictors of outcome, independent of risk factors and the type of ischemic stroke, it is expected that patients with AF would have a worse outcome because of these characteristics [8, 14]. Thus, AF was not an independent predictor of poor outcome, unlike older age and a higher NIHSS score. Similarly, in our study, AF was also not an independent predictor of poor outcome, as opposed to older age, higher NIHSS score and lower ASPECT score on admission, as well as higher blood glucose levels on admission. Moreover, some studies have shown that among patients with severe clinical ischemic stroke (NIHSS score [greater than or equal to] 10) AF was associated with a better outcome [9]. A study by Shang Feng et al. analyzed the outcomes in subgroups of patients, depending on their NIHSS scores (scores above and below 10). In the group of patients with a NIHSS score over 10, a favorable outcome after three months was seen in 31% of patients with AF, and 8% of patients without AF (p= 0.005), and mortality rates were 8% among cases with AF and 17% among patients without AF (p = 0.168). This study concluded that, if NIHSS score on admission was above 10, patients with AF had a better outcome after IVT than those without AF. However, the most reliable results on the efficacy of IVT in AIS patients with AF were obtained from studies that included only patients with AF and compared those who were treated with IVT and those not treated with IVT [16]. The conclusion of those studies was that patients treated with IVT had a much better outcome compared to those who were not treated with IVT. Similar results were obtained in a multicenter study in China [17]. In this study, administration of IVT was an independent predictor of a favorable outcome (OR 5.73, 95% CI 2.4 - 13.7; p < 0.001) in patients with AIS and AF.

From the pathophysiological point of view, the success of IVT treatment in ischemic stroke caused by AF should be the most conclusive. In most cases, cardio-embolic stroke is caused by the red thrombus, which essentially consists of erythrocytes and fibrin [18, 19]. In cases with red thrombus, IVT is much more effective, as demonstrated by animal studies [20]. This finding is supported by clinical studies that have demonstrated successful recanalization after the IVT therapy in ischemic stroke caused by AF [21, 22]. The controversial results about the efficacy of IVT in patients with AIS and AF can be explained by additional factors that are often not considered when assessing the outcome at three months after IVT. Namely, AF is associated mainly with chronic heart failure [23, 24], which often causes reduced premorbid functionality (premorbid mRS [greater than or equal to] 1) and a reduced ability for maximum mobility during rehabilitation treatment. Given that patients with AF are older and have a clinically more severe ischemic stroke, they often, even after successful recanalization and initial neurological improvement, have persisting neurological deficits requiring extended hospitalization [24], which itself carries the risk of further complications and after three months, patients do not reach mRS [less than or equal to] 2, i.e., a favorable outcome.

Limitations of our study were the small number of patients with AF. Secondly, the lack of a control group of AIS patients with AF who were not treated with IVT, whose outcome would be compared with thrombolysis patients. Also, the study included only patients with the same type of cerebral infarction (TACI, PACI or POCI), and if it included patients with different types, it would have given more reliable and perhaps different results. However, this would require more patients, and it should be a topic for future researches.

Conclusion

Patients with acute ischemic stroke and atrial fibrillation, treated with intravenous thrombolysis, had a worse outcome compared with patients without atrial fibrillation. However, patients with atrial fibrillation were older, had more severe neurological deficits, larger cerebral infarction and more commonly developed hemorrhagic transformation, which were likely the main reasons for their poorer treatment outcome.

References

(1.) Dewar RI, Lip GY. Identification, diagnosis and assessment of atrial fibrillation. Heart. 2007;93(1):25-8.

(2.) Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.

(3.) Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-236.

(4.) Duricic S, Rabi Zikic T, Zikic M. Risk factors of the first stroke. Med Pregl. 2015;68(1-2):17-21.

(5.) Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.

(6.) Wahlgren N, Moreira T, Michel P, Steiner T, Jansen O, Cognard C, et al. Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int J Stroke. 2016;11(1):134-47.

(7.) Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-35.

(8.) Kimura K, Iguchi Y, Shibazaki K, Iwanaga T, Yamashita S, Aoki J. IV t-PA therapy in acute stroke patients with atrial fibrillation. J Neurol Sci. 2009;276(1-2):6-(8.)

(9.) Sung SF, Chen YW, Tseng MC, Ong CT, Lin HJ. Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke. Clin Neurol Neurosurg. 2013;115(7):892-5.

(10.) Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25 (11):2220-6.

(11.) Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of aquantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670-4.

(12.) Hacke W, Kaste M, Bluhmki E, Brozman M, DAaAaAeA valos A, Guidetti et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-29.

(13.) Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337(8756):1521-6.

(14.) Padjen V, Bodenant M, Jovanovic DR, Ponchelle-Dequatre N, Novakovic N, Cordonnier C, et al. Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia. J Neurol. 2013;260(12):3049-54.

(15.) Yaghi S, Hinduja A, Bianchi N. Predictors of major improvement after intravenous thrombolysis in acute ischemic stroke. Int J Neurosci. 2016;126(1):67-9.

(16.) Ogata J, Yutani C, Otsubo R, Yamanishi H, Naritomi H, Yamaguchi T, et al. Heart and vessel pathology underlying brain infarction in 142 stroke patients. Ann Neurol. 2008;63(6):770-81.

(17.) Zhao Q, Li X, Dong W, Ye M, Cao Y, Zhang M, et al. Factors associated with thrombolysis outcome in ischemic stroke patients with atrial fibrillation. Neurosci Bull. 2016;32(2):145-52.

(18.) Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79(4):920-8.

(19.) Whitesell RT, Steenburg SD. Imaging findings of acute intravascular thrombus on non-enhanced computed tomography. Emerg Radiol. 2014;21(3):271-7.

(20.) Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-SabAaAaAe J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke. 2004;35(2):486-90.

(21.) Puig J, Pedraza S, Demchuk A, Daunis-I-Estadella J, Termes H, Blasco G, et al. Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator. Am J Neuroradiol. 2012;33(1):90-6.

(22.) Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke. 2004;35(1):151-6.

(23.) Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003;107(23):2920-5.

(24.) Seet RC, Zhang Y, Rabinstein AA, Wijdicks EF. Risk factors and consequences of atrial fibrillation with rapid ventricular response in patients with ischemic stroke treated with intravenous thrombolysis. J Stroke Cerebrovasc Dis. 2013;22(2):161-5.

Zeljko ZIVANOVIC (1,2), Dragan ADAMOVIC (1), Aleksandra LUCIC PROKIN (1,3), Timea KOKAI ZEKIC (3), Jelena SEKARIC (3) and PETAR SLANKAMENAC (1,2)

University of Novi Sad, Faculty of Medicine (1) Clinical Center of Vojvodina, Novi Sad

Clinic of Neurology (2)

Emergency Center, Department of Neurology (3)
Table 1. Patients' characteristics
Tabela 1. Klinicke karakteristike pacijenata

                                                       Group with AF
                                                       (n = 74)/Grupa sa
                                                       AF (n = 74)

Demographic/Demografske karakteristike
Age, years/Starost, godine                              69.4[+ or -]9.2
Gender, male/Pol, muski                                 42 (56.8%)
Risk factors/Faktori rizika
Arterial hypertension/Arterijska hipertenzija           68 (91.9%)
Diabetes/Dijabetes                                      10 (13.5%)
Hyperlipoproteinemia/Hiperlipoproteinemija              38 (51.4%)
Smoking/Pusenje                                         13 (17.6%)
Current stroke/Aktuelno stanje
NIHSS score on admission/NIHSS skor na prijemu          15.0[+ or -]4.1
Glycemia on admission/Glikemija na prijemu, mmol/l       7.7[+ or -]2.8
Previous antiplatelet therapy
Prethodna antiagregaciona terapija                      36 (48.7%)
Previous statin therapy/Prethodna terapija statinima     8 (10.8%)
ASPECT score/ASPECT skor                                 9.2[+ or -]1.1
Leukoaraiosis/Leukoarajoza                              12 (16.2%)
OTT on admission, min./OTT na prijemu, min.            164.9[+ or -]72.9
Stroke subtype/Tip infarkta mozga
TACI                                                    35 (47.3%)
PACI                                                    34 (45.9%)
LACI                                                     2 (2.7%)
POCI                                                     3 (4.1%)

                                                       Group without AF
                                                       (n = 114)/Grupa
                                                       bez AF (n = 114)

Demographic/Demografske karakteristike
Age, years/Starost, godine                              62.6[+ or -]10.2
Gender, male/Pol, muski                                 81 (71.1%)
Risk factors/Faktori rizika
Arterial hypertension/Arterijska hipertenzija           100 (87.7%)
Diabetes/Dijabetes                                       23 (20.2%)
Hyperlipoproteinemia/Hiperlipoproteinemija               64 (56.1%)
Smoking/Pusenje                                          40 (35.1%)
Current stroke/Aktuelno stanje
NIHSS score on admission/NIHSS skor na prijemu           12.1[+ or -]4.5
Glycemia on admission/Glikemija na prijemu, mmol/l        8.1[+ or -]3.7
Previous antiplatelet therapy
Prethodna antiagregaciona terapija                       32 (28.1%)
Previous statin therapy/Prethodna terapija statinima      8 (7.0%)
ASPECT score/ASPECT skor                                  9.2[+ or -]1.1
Leukoaraiosis/Leukoarajoza                               17 (14.9%)
OTT on admission, min./OTT na prijemu, min.            167.5[+ or -]52.7
Stroke subtype/Tip infarkta mozga
TACI                                                    22 (19.3%)
PACI                                                    51 (44.5%)
LACI                                                    25 (21.9%)
POCI                                                    15 (13.2%)

                                                       p (significance)
                                                       p (statisticka
                                                       znacajnost)

Demographic/Demografske karakteristike
Age, years/Starost, godine                             <0.0001
Gender, male/Pol, muski                                 0.04
Risk factors/Faktori rizika
Arterial hypertension/Arterijska hipertenzija           0.36
Diabetes/Dijabetes                                      0.24
Hyperlipoproteinemia/Hiperlipoproteinemija              0.51
Smoking/Pusenje                                         0.009
Current stroke/Aktuelno stanje
NIHSS score on admission/NIHSS skor na prijemu          0.0001
Glycemia on admission/Glikemija na prijemu, mmol/l      0.42
Previous antiplatelet therapy
Prethodna antiagregaciona terapija                      0.004
Previous statin therapy/Prethodna terapija statinima    0.36
ASPECT score/ASPECT skor                                0.67
Leukoaraiosis/Leukoarajoza                              0.08
OTT on admission, min./OTT na prijemu, min.             0.77
Stroke subtype/Tip infarkta mozga
TACI
PACI                                                   <0.0001
LACI
POCI

Legend: AF--Atrial fibrillation; NIHSS score - The National Institutes
of Health Stroke Scale; MAP-Mean Arterial Pressure; ASPECT
score - Alberta Stroke Program Early CT score; OTT- Onset to-treatment
time; TACI - total anterior circulation infarction; PACI - partial
anterior circulation infarction; LACI--lacunar infarction;
POCI - posterior circulation infarction
Legenda: AF--atrijalna fibrilacija; NIHSS skor--Nacionalni vodic za
skor kod akutnog ishemijskog mozdanog udara; MAP--srednji arterijski
pritisak; ASPECT skor--Alberta program mozdanog udara--rani rezultat
kompjuterizovane tomografije; OTT--vreme pocetka tretmana;
TACI--totalni anteriorni cirkulatorni infarkt; PACI--delimicni
anteriorni cirkulatorni infarkt; LACI--lakunarni infarkt;
POCI--infarkt posteriorne cirkulacije

Table 2. Outcome of intravenous thrombolysis
Tabela 2. Ishod nakon intravenske trombolize

                                                         Group with AF
                                                         n = 74/Grupa
                                                         sa AF (n = 74)

Neurological improvement at 24 h
Neurolosko poboljsanje nakon 24 h                        23 (31.1%)
Good outcome (mRS 0-2)/Povoljan ishod (mRS 0-2)          32 (43.2%)
Hemorrhagic transformation/Hemoragijska transformacija   22 (29.7%)
sICH/Simptomatska intracerebralna hemoragija              7 (9.5%)
mRS 6/Modifikovana Rankinova skala                       23 (31.1%)

                                                         Group without
                                                         AF
                                                         n = 114/Grupa
                                                         bez
                                                         AF (n = 114)

Neurological improvement at 24 h
Neurolosko poboljsanje nakon 24 h                        48 (42.1%)
Good outcome (mRS 0-2)/Povoljan ishod (mRS 0-2)          70 (61.4%)
Hemorrhagic transformation/Hemoragijska transformacija   12 (10.5%)
sICH/Simptomatska intracerebralna hemoragija              0 (0.0%)
mRS 6/Modifikovana Rankinova skala                        9 (7.9%)

                                                        p (significance)
                                                        p (statisticka
                                                        znacajnost)

Neurological improvement at 24 h
Neurolosko poboljsanje nakon 24 h                        0.12
Good outcome (mRS 0-2)/Povoljan ishod (mRS 0-2)          0.01
Hemorrhagic transformation/Hemoragijska transformacija  <0.001
sICH/Simptomatska intracerebralna hemoragija            <0.001
mRS 6/Modifikovana Rankinova skala                      <0.001

Legend: AF--atrial fibrillation, mRS--modified Rankin Scale;
sICH--symptomatic intracerebral hemorrhage.
Legenda: AF--atrijalna fibrilacija, mRS--modifikovana Rankinova skala;
sICH--simptomatska intracerebralna hemoragija.
COPYRIGHT 2017 Drustvo Lekara Vojvodine
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Zivanovic, Zeljko; Adamovic, Dragan; Prokin, Aleksandra Lucic; Zekic, Timea Kokai; Sekaric, Jelena;
Publication:Medicinski Pregled
Article Type:Report
Date:Jul 1, 2017
Words:4738
Previous Article:TRANSOSSEOUS OSTEOSYNTHESIS - THE ILIZAROV METHOD/TRANSOSEALNA OSTEOSINTEZA - ILIZAROVA METODA.
Next Article:COMPARISON OF THE DIAGNOSTIC VALUE OF TWO ASSAYS FOR SPECIFIC IMMUNOGLOBULIN E IN SUSPECTED BETA LACTAM ALLERGY/PORE[ETH]ENJE DIJAGNOSTICKE VREDNOSTI...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters